|
1. Minchinton AI, Tannock IF. Drug penetration in solid tumours. Nat Rev Cancer. 2006; 6(8):583-92. 2. Leader B, Baca QJ, Golan DE. Protein therapeutics: a summary and pharmacological classification. Nat Rev Drug Discov. 2008;7(1):21-39. 3. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci. 2009;46(4):167-89. 4. Held J, Schulze-Osthoff K. Potential and caveats of TRAIL in cancer therapy. Drug Resist Updat. 2001;4(4):243-52. 5. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235-71. 6. Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35(4):495-516. 7. Viard-Leveugle I, Gaide O, Jankovic D, Feldmeyer L, Kerl K, Pickard C, et al. TNF-α and IFN-γ are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. J Invest Dermatol. 2013;133(2):489-98. 8. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271(22):12687-90. 9. Tavallaei O, Bandehpour M, Nafissi-Varcheh N, Kazemi B. Production and secretion of TNF related apoptosis inducing ligand (TRAIL/Apo2L) in the Escherichia coli periplasm using PhoA signal peptide. J Rep Pharm Sci. 2014;3(1):90-98. 10. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2010; 28(9):1527-33. 11. Hameed AG, Arnold ND, Chamberlain J, Pickworth JA, Paiva C, Dawson S, et al. Inhibition of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) reverses experimental pulmonary hypertension. J Exp Med. 2012; 209(11):1919-35. 12. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell. 2001; 23;104(4):487-501. 13. Willms A, Schittek H, Rahn S, Sosna J, Mert U, Adam D, et al. Impact of p53 status on TRAIL-mediated apoptotic and non-apoptotic signaling in cancer cells. PLoS One. 2019; 14(4):e0214847. 14. Zhong HH, Wang HY, Li J, Huang YZ. TRAIL-based gene delivery and therapeutic strategies. Acta pharmacologica Sinica. 2019;40(11):1373-85. 15. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS, et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol. 2010;28:2839-2846. 16. T Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol. 2015; 5:69. 17. He F. Laemmli-sds-page. Bio-protoc. 2011; e80-e80. DOI:10.21769/BioProtoc.80. 18. Jensen EC. The basics of western blotting. Anat Rec. 2012; 295(3):369-71. 19. Butt TR, Edavettal SC, Hall JP, Mattern MR. SUMO fusion technology for difficult-to-express proteins. Protein Expr Purif. 2005; 43(1): 1-9. 20. Kaur J, Kumar A, Kaur J. Strategies for optimization of heterologous protein expression in E. coli: Roadblocks and reinforcements. Int J Biol Macromol. 2018;106: 803-822. 21. Tham HY, Song AA, Yusoff K, Tan GH. Effect of different cloning strategies in pet-28a on solubility and functionality of a staphylococcal phage endolysin. Biotechniques. 2020;69(3): 161-70. 22. Tarahomjoo S, Bandehpour M, Aghaebrahimian M, Ahangaran S. Soluble Diphtheria Toxin Variant, CRM 197 was Obtained in Escherichia coli at High Productivity Using SUMO Fusion and an Adjusted Expression Strategy. Protein Pept Lett. 2022; 29(4): 350-359. 23. halilvand AB, Aminzadeh S, Sanati MH, Mahboudi F. Cytoplasmic soluble Lispro insulin production in Escherichia coli, product yield optimization and physiochemical characterization. Biochem Eng J. 2022; 182: 108410.
|
